• 1

Peripheral Arterial Occlusive Disease – Allogeneic

We are recruiting patients with peripheral arterial occlusive disease (PAOD) for a multicentric, randomized, placebo-controlled, double-blind phase I/IIa clinical trial.

The aim of the trial is to examine the efficacy and safety of allogeneic ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) in patients with PAOD. Primary endpoints are the percentage of wound size reduction and the occurrence of adverse events.

For this trial 76 patients will be recruited at 11 sites in Germany, Austria, United Kingdom (UK) and Czech Republic.

For the manufacturing process of the allogeneic ABCB5+ MSCs we are using a patent hold by the Brigham and Women’s Hospital, Boston/USA, and the Children’s Hospital, Boston/USA, in cooperation with our scientific partner Prof. Dr. Markus Frank.

More information about the trial can be found HERE (ClinicalTrials.gov) or HERE (EU Clinical Trials Register).

Background information about the use of ABCB5+ MSCs in PAOD can be found HERE.

<< back

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.